Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Forecast & Price Target
Acrivon Therapeutics, Inc. Common Stock · NASDAQ
$1.57-0.03 (-1.87%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Acrivon Therapeutics, Inc. Common Stock, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $8.00 to $19.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $11.67 sits 643% above the current $1.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.52 next quarter toward $-1.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Acrivon Therapeutics, Inc. Common Stock.
As of Jul, 3 of 3 firms rate ACRV a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACRV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-0.59 – $-0.49 · 7 analysts · +11% YoY
Next period, 7 analysts expect Acrivon Therapeutics, Inc. Common Stock to earn $-0.52 a share (range $-0.59 – $-0.49), versus $-0.47 a year earlier. Full-year consensus is $-2.07, growing to $-1.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $145.5K next year.
Top analysts covering Acrivon Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACRV.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$13.00+728.0% to target
Overall win rate
50%
+ Follow
#2
Li Watsek
Cantor Fitzgerald · Rank #218
Buy
No targeton ACRV
Overall win rate
38%
+ Follow
#3
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$8.00+409.6% to target
Overall win rate
29%
+ Follow
#4
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$19.00+1110.2% to target
Overall win rate
22%
+ Follow
#5
Aydin Huseynov
Ladenburg Thalmann · Rank #361
Buy
$16.00+919.1% to target
Overall win rate
34%
+ Follow
ACRV stock forecast FAQ
What is ACRV's average 12-month price target?+
The 3 analysts with a live target average $11.67 for Acrivon Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $19.00 high to a $8.00 low.
Is ACRV stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ACRV?+
The Street-high target is $19.00 (HC Wainwright & Co.), and the Street-low is $8.00 (Piper Sandler). The average of all 3 active targets is $11.67.
How many Wall Street analysts cover ACRV?+
3 analysts have an active rating on Acrivon Therapeutics, Inc. Common Stock, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACRV?+
Among analysts who currently cover ACRV, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $13.00 target.
What is Acrivon Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-0.59 – $-0.49) across 7 analysts. Full-year EPS is projected at $-2.07, rising to $-1.95 the following year.
How much revenue is Acrivon Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $145.5K next year.
Have analysts been upgrading or downgrading ACRV lately?+
As of Jul, 3 of 3 firms rate ACRV a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACRV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
